US2023159595A1PendingUtilityA1

Polypeptides for use in self-assembling protein nanostructures

77
Assignee: UNIV WASHINGTONPriority: Nov 3, 2014Filed: Sep 22, 2022Published: May 25, 2023
Est. expiryNov 3, 2034(~8.3 yrs left)· nominal 20-yr term from priority
Inventors:David BakerJacob BaleNeil P. KingWilliam H. ShefflerDaniel Ellis
C07K 14/00
77
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Synthetic nanostructures, polypeptides that are useful, for example, in making synthetic nanostructures, and methods for using such synthetic nanostructures are disclosed herein.

Claims

exact text as granted — not AI-modified
1 .- 20 . (canceled) 
     
     
         21 . A self-assembling icosahedral protein nanostructure, comprising:
 20 trimeric components having 3-fold symmetry, each trimeric component comprising 3 first subunits, wherein each first subunit comprises a polypeptide having a polypeptide sequence that is at least 80% identical to SEQ ID NO: 7 or 29-31; and   12 pentameric components having 5-fold symmetry, each pentameric component comprising 5 second subunits, wherein each second subunit comprises a polypeptide having a polypeptide sequence that is at least 80% identical to SEQ ID NO: 8 or 32-34.   
     
     
         22 . The nanostructure of  claim 21 , wherein the polypeptide sequence of each first subunit is at least 90% identical to SEQ ID NO: 7 or 29-31; and
 wherein the polypeptide sequence of each second subunit is at least 90% identical to SEQ ID NO: 8 or 32-34.   
     
     
         23 . The nanostructure of  claim 21 , wherein the polypeptide sequence of each first subunit is at least 95% identical to SEQ ID NO: 7 or 29-31; and
 wherein the polypeptide sequence of each second subunit is at least 95% identical to SEQ ID NO: 8 or 32-34.   
     
     
         24 . The nanostructure of  claim 23 , wherein the trimeric components and the pentameric components form an I53 icosahedral architecture. 
     
     
         25 . The nanostructure of  claim 21 , wherein the polypeptide sequence of each first subunit is SEQ ID NO: 7; and
 wherein the polypeptide sequence of each second subunit is SEQ ID NO: 8.   
     
     
         26 . The nanostructure of  claim 21 , wherein the polypeptide sequence of each first subunit is SEQ ID NO: 7; and
 wherein the polypeptide sequence of each second subunit is SEQ ID NO: 32.   
     
     
         27 . The nanostructure of  claim 21 , wherein the polypeptide sequence of each first subunit is SEQ ID NO: 7; and
 wherein the polypeptide sequence of each second subunit is SEQ ID NO: 33.   
     
     
         28 . The nanostructure of  claim 21 , wherein the polypeptide sequence of each first subunit is SEQ ID NO: 7; and
 wherein the polypeptide sequence of each second subunit is SEQ ID NO: 34.   
     
     
         29 . The nanostructure of  claim 28 , wherein the trimeric components and the pentameric components form an I53 icosahedral architecture. 
     
     
         30 . The nanostructure of  claim 21 , wherein the polypeptide sequence of each first subunit is SEQ ID NO: 29; and
 wherein the polypeptide sequence of each second subunit is SEQ ID NO: 8.   
     
     
         31 . The nanostructure of  claim 21 , wherein the polypeptide sequence of each first subunit is SEQ ID NO: 29; and
 wherein the polypeptide sequence of each second subunit is SEQ ID NO: 32.   
     
     
         32 . The nanostructure of  claim 21 , wherein the polypeptide sequence of each first subunit is SEQ ID NO: 29; and
 wherein the polypeptide sequence of each second subunit is SEQ ID NO: 33.   
     
     
         33 . The nanostructure of  claim 21 , wherein the polypeptide sequence of each first subunit is SEQ ID NO: 29; and
 wherein the polypeptide sequence of each second subunit is SEQ ID NO: 34.   
     
     
         34 . The nanostructure of  claim 21 , wherein the polypeptide sequence of each first subunit is SEQ ID NO: 30; and
 wherein the polypeptide sequence of each second subunit is SEQ ID NO: 8.   
     
     
         35 . The nanostructure of  claim 21 , wherein the polypeptide sequence of each first subunit is SEQ ID NO: 30; and
 wherein the polypeptide sequence of each second subunit is SEQ ID NO: 32.   
     
     
         36 . The nanostructure of  claim 21 , wherein the polypeptide sequence of each first subunit is SEQ ID NO: 30; and
 wherein the polypeptide sequence of each second subunit is SEQ ID NO: 33.   
     
     
         37 . The nanostructure of  claim 21 , wherein the polypeptide sequence of each first subunit is SEQ ID NO: 30; and
 wherein the polypeptide sequence of each second subunit is SEQ ID NO: 34.   
     
     
         38 . The nanostructure of  claim 21 , wherein the polypeptide sequence of each first subunit is SEQ ID NO: 31; and
 wherein the polypeptide sequence of each second subunit is SEQ ID NO: 8.   
     
     
         39 . The nanostructure of  claim 21 , wherein the polypeptide sequence of each first subunit is SEQ ID NO: 31; and
 wherein the polypeptide sequence of each second subunit is SEQ ID NO: 32.   
     
     
         40 . The nanostructure of  claim 21 , wherein the polypeptide sequence of each first subunit is SEQ ID NO: 31; and
 wherein the polypeptide sequence of each second subunit is SEQ ID NO: 33.   
     
     
         41 . The nanostructure of  claim 21 , wherein the polypeptide sequence of each first subunit is SEQ ID NO: 31; and
 wherein the polypeptide sequence of each second subunit is SEQ ID NO: 34.   
     
     
         42 . The nanostructure of  claim 21 , wherein the polypeptide sequence of each first subunit is at least 95% identical to SEQ ID NO: 7. 
     
     
         43 . The nanostructure of  claim 21 , wherein the polypeptide sequence of each first subunit is at least 95% identical to SEQ ID NO: 29. 
     
     
         44 . The nanostructure of  claim 21 , wherein the polypeptide sequence of each first subunit is at least 95% identical to SEQ ID NO: 30. 
     
     
         45 . The nanostructure of  claim 21 , wherein the polypeptide sequence of each first subunit is at least 95% identical to SEQ ID NO: 31. 
     
     
         46 . The nanostructure of  claim 21 , wherein the polypeptide sequence of each second subunit is at least 95% identical to SEQ ID NO: 8. 
     
     
         47 . The nanostructure of  claim 21 , wherein the polypeptide sequence of each second subunit is at least 95% identical to SEQ ID NO: 32. 
     
     
         48 . The nanostructure of  claim 21 , wherein the polypeptide sequence of each second subunit is at least 95% identical to SEQ ID NO: 33. 
     
     
         49 . The nanostructure of  claim 21 , wherein the polypeptide sequence of each second subunit is at least 95% identical to SEQ ID NO: 34. 
     
     
         50 . The nanostructure of  claim 21 , wherein the polypeptide sequence of each first subunit is SEQ ID NO: 7. 
     
     
         51 . The nanostructure of  claim 21 , wherein the polypeptide sequence of each first subunit is SEQ ID NO: 29. 
     
     
         52 . The nanostructure of  claim 21 , wherein the polypeptide sequence of each first subunit is SEQ ID NO: 30. 
     
     
         53 . The nanostructure of  claim 21 , wherein the polypeptide sequence of each first subunit is SEQ ID NO: 31. 
     
     
         54 . The nanostructure of  claim 21 , wherein the polypeptide sequence of each second subunit is SEQ ID NO: 8. 
     
     
         55 . The nanostructure of  claim 21 , wherein the polypeptide sequence of each second subunit is SEQ ID NO: 32. 
     
     
         56 . The nanostructure of  claim 21 , wherein the polypeptide sequence of each second subunit is SEQ ID NO: 33. 
     
     
         57 . The nanostructure of  claim 21 , wherein the polypeptide sequence of each second subunit is SEQ ID NO: 34. 
     
     
         58 . The nanostructure of  claim 21 , wherein the polypeptide sequence of each first subunit is identical to SEQ ID NO: 7 or 29-31 at at least 3 of interface amino acid positions 25, 29, 33, 54, and 57; and
 wherein the polypeptide sequence of each second subunit is identical to SEQ ID NO: 8 or 32-34 at at least 3 of interface amino acid positions 24, 28, 36, 124, 125, 127, 128, 129, 131, 132, 133, 135, and 139.   
     
     
         59 . The nanostructure of  claim 23 , wherein the polypeptide sequence of each first subunit is identical to SEQ ID NO: 7 or 29-31 at at least 3 of interface amino acid positions 25, 29, 33, 54, and 57; and
 wherein the polypeptide sequence of each second subunit is identical to SEQ ID NO: 8 or 32-34 at at least 3 of interface amino acid positions 24, 28, 36, 124, 125, 127, 128, 129, 131, 132, 133, 135, and 139.   
     
     
         60 . The nanostructure of  claim 24 , wherein the polypeptide sequence of each first subunit is identical to SEQ ID NO: 7 or 29-31 at at least 3 of interface amino acid positions 25, 29, 33, 54, and 57; and
 wherein the polypeptide sequence of each second subunit is identical to SEQ ID NO: 8 or 32-34 at at least 3 of interface amino acid positions 24, 28, 36, 124, 125, 127, 128, 129, 131, 132, 133, 135, and 139.

Join the waitlist — get patent alerts

Track US2023159595A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.